Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data

被引：7

作者：

Atesoglu, Elif Birtas ^{[1
]}

Gulbas, Zafer ^{[2
]}

Uzay, Ant ^{[3
]}

Ozcan, Muhit ^{[4
]}

Ozkalemkas, Fahir ^{[5
]}

Dal, Mehmet Sinan ^{[6
]}

Kalyon, Hakan ^{[1
]}

Akay, Olga Meltem ^{[1
]}

Deveci, Burak ^{[7
]}

Bekoz, Huseyin ^{[8
]}

Sevindik, Omur Gokmen ^{[8
]}

Toptas, Tayfur ^{[9
]}

Yilmaz, Fergun ^{[9
]}

Koyun, Derya ^{[4
]}

Alkis, Nihan ^{[10
]}

Alacacioglu, Inci ^{[11
]}

Sonmez, Mehmet ^{[12
]}

Yavasoglu, Irfan ^{[13
]}

Tombak, Anil ^{[14
]}

Mehtap, Ozgur ^{[15
]}

Kurnaz, Fatih ^{[16
]}

Yuce, Orhan Kemal ^{[17
]}

Karakus, Volkan ^{[18
]}

Turgut, Mehmet ^{[19
]}

Kurekci, Derya Deniz ^{[19
]}

Ayer, Mesut ^{[20
]}

Keklik, Muzaffer ^{[21
]}

Buyuktas, Deram ^{[22
]}

Ozbalak, Murat ^{[20
]}

Ferhanoglu, Burhan ^{[1
,23
,24
]}

机构：

[1] Koc Univ, Dept Internal Med, Div Hematol, Sch Med, Istanbul, Turkiye

[2] Anadolu Med Ctr, Div Hematol, Kocaeli, Turkiye

[3] Acibadem Atakent Hosp, Div Hematol, Istanbul, Turkiye

[4] Ankara Univ, Dept Internal Med, Div Hematol, Med Fac, Ankara, Turkiye

[5] Uludag Univ, Dept Internal Med, Div Hematol, Med Fac, Bursa, Turkiye

[6] Dr Abdurrahman Yurtaslan Ankara Oncol Hosp, Div Hematol, Ankara, Turkiye

[7] Medstar Hosp, Div Hematol, Antalya, Turkiye

[8] Medipol Univ, Dept Internal Med, Div Hematol, Med Fac, Istanbul, Turkiye

[9] Marmara Univ, Dept Internal Med, Div Hematol, Med Fac, Istanbul, Turkiye

[10] Bursa City Hosp, Div Hematol, Bursa, Turkiye

[11] Dokuz Eylul Univ, Dept Internal Med, Div Hematol, Med Fac, Izmir, Turkiye

[12] Karadeniz Tech Univ, Dept Internal Med, Div Hematol, Med Fac, Trabzon, Turkiye

[13] Adnan Menderes Univ, Dept Internal Med, Div Hematol, Med Fac, Aydin, Turkiye

[14] Mersin Univ, Dept Internal Med, Div Hematol, Med Fac, Mersin, Turkiye

[15] Kocaeli Univ, Dept Internal Med, Div Hematol, Med Fac, Kocaeli, Turkiye

[16] Kocaeli Medicalpark Hosp, Div Hematol, Kocaeli, Turkiye

[17] Akdeniz Univ, Dept Internal Med, Div Hematol, Med Fac, Antalya, Turkiye

[18] Antalya Res & Training Hosp, Div Hematol, Antalya, Turkiye

[19] Ondokuzmayis Univ, Dept Internal Med, Div Hematol, Med Fac, Samsun, Turkiye

[20] Basaksehir Cam ve Sakura City Hosp, Div Hematol, Istanbul, Turkiye

[21] Erciyes Univ, Dept Internal Med, Div Hematol, Med Fac, Kayseri, Turkiye

[22] VKV Amer Hosp, Div Hematol, Istanbul, Turkiye

[23] Koc Univ, Sch Med, Dept Hematol, Istanbul, Turkiye

[24] VKV Amer Hosp, Dept Hematol, Istanbul, Turkiye

来源：

HEMATOLOGICAL ONCOLOGY | 2023年 / 41卷 / 04期

关键词：

bispecific antibodies; glofitamab; relapsed; refractory diffuse large B-cell lymphoma; SINGLE-ARM; OPEN-LABEL; MULTICENTER;

D O I：

10.1002/hon.3174

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patients with relapsed/refractory (R/R) B-cell lymphoma. However, the real-world data of patients of all ages with no strict selection criteria are still lacking. Herein, this retrospective study aimed to evaluate the outcomes of diffuse large B-cell lymphoma (DLBCL) patients who received glofitamab via compassionate use in Turkey. Forty-three patients from 20 centers who received at least one dose of the treatment were included in this study. The median age was 54 years. The median number of previous therapies was 4, and 23 patients were refractory to first-line treatment. Twenty patients had previously undergone autologous stem cell transplantation. The median follow-up time was 5.7 months. In efficacy-evaluable patients, 21% and 16% of them achieved complete response and partial response, respectively. The median response duration was 6.3 months. The median progression-free survival (PFS) and overall survival (OS) was 3.3 and 8.8 months, respectively. None of the treatment-responsive patients progressed during the study period, and their estimated 1-year PFS and OS rate was 83%. The most frequently reported toxicity was hematological toxicity. Sixteen patients survived, while 27 died at the time of the analysis. The most common cause of death was disease progression. One patient died of cytokine release syndrome during the first cycle after receiving the first dose of glofitamab. Meanwhile, two patients died due to glofitamab-related febrile neutropenia. This is the largest real-world study on the effectiveness and toxicity of glofitamab treatment in R/R DLBCL patients. The median OS of 9 months seems promising in this heavily pretreated group. The toxicity related mortality rates were the primary concerns in this study.

引用

页码：663 / 673

页数：11

共 50 条

[31] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, Stephen J.
Bishop, Michael R.
Tam, Constantine S.
Waller, Edmund K.
Borchmann, Peter
McGuirk, Joseph P.
Jaeger, Ulrich
Jaglowski, Samantha
Andreadis, Charalambos
Westin, Jason R.
Fleury, Isabelle
Bachanova, Veronika
Foley, S. Ronan
Ho, P. Joy p
Mielke, Stephan
Magenau, John M.
Holte, Harald
Pantano, Serafino
Pacaud, Lida B.
Awasthi, Rakesh
Chu, Jufen
Anak, Ozlem
Salles, Gilles
Maziarz, Richard T.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01): : 45 - 56
[32] Novel agents in relapsed/refractory diffuse large B-cell lymphoma
Varma, Gaurav
Goldstein, Jordan
Advani, Ranjana H.
[J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 : 92 - 106
[33] CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: REAL-WORLD DATA FROM LMU MUNICH
Bucklein, V.
Blumenberg, V.
Schmidt, C.
Rejeski, K.
Ruzicka, M.
Mueller, N.
Reischer, A.
von Baumgarten, L.
Voelkl, A.
Wagner, B.
Humpe, A.
Tischer, J.
Stemmler, H.
von Bergwelt, M.
Subklewe, M.
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A48 - A49
[34] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
Dietliker, N.
Kiesel, H.
Mueller, R.
Mueller, A. M.
Manz, M.
Zenz, T.
Rosler, W.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
[35] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Salles, Gilles
Dlugosz-Danecka, Monika
Ghesquieres, Herve
Jurczak, Wojciech
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
[36] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, Laurie H.
Herrera, Alex F.
Flowers, Christopher R.
Kamdar, Manali K.
McMillan, Andrew
Hertzberg, Mark
Assouline, Sarit
Kim, Tae Min
Kim, Won Seog
Ozcan, Muhit
Hirata, Jamie
Penuel, Elicia
Paulson, Joseph N.
Cheng, Ji
Ku, Grace
Matasar, Matthew J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
[37] Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused"
Kesireddy, Meghana
Lunning, Matthew A.
[J]. ONCOLOGY-NEW YORK, 2022, 36 (06): : 360 - 369
[38] Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Harris, Leonard Jeff
Patel, Kruti
Martin, Michael
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 12
[39] Phylogenetic Evolution in Refractory/Relapsed Diffuse Large B-Cell Lymphoma
Ruminy, Philippe
Rainville, Vinciane
Mareschal, Sylvain
Etancelin, Pascaline
Joly, Berangere
Picquenot, Jean-Michel
Bastard, Christian
Tilly, Herve
Jardin, Fabrice
[J]. BLOOD, 2012, 120 (21)
[40] Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma
Vacirca, J. L.
Acs, P. I.
Shimkus, B. J.
Rosen, P. J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →